Comparative Pharmacology
Head-to-head clinical analysis: LORTAB versus TYMTRAN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LORTAB versus TYMTRAN.
LORTAB vs TYMTRAN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Hydrocodone is a mu-opioid receptor agonist; acetaminophen inhibits cyclooxygenase (COX) and modulates pain pathways centrally.
TYMTRAN (pegvorhyaluronidase alfa) is a recombinant human hyaluronidase that degrades hyaluronic acid (HA) in the tumor microenvironment, reducing interstitial fluid pressure and improving drug penetration.
1-2 tablets (each containing 5 mg hydrocodone/325 mg acetaminophen) orally every 4-6 hours as needed for pain. Maximum acetaminophen 3000 mg/day.
Intramuscular injection: 0.5 mg/kg body weight (maximum 25 mg per dose) administered once daily for 2 to 3 days. Oral: Not available.
None Documented
None Documented
Hydrocodone: 3.3-4.4 hours in adults; prolonged in hepatic/renal impairment (up to 6-8 hours). Clinical context: requires 4-6 hour dosing intervals; steady-state in ~24 hours.
Terminal elimination half-life is 12-15 hours in healthy adults, allowing twice-daily dosing; extended to 20-25 hours in hepatic impairment.
Renal: ~90% (unchanged: ~5% hydrocodone, ~60% hydromorphone and other conjugates; codeine-like metabolites). Biliary/fecal: minor (<10%).
Primarily hepatic metabolism via CYP3A4, with 70% excreted in feces as metabolites and 20% in urine as unchanged drug and metabolites.
Category C
Category C
Opioid analgesic combination
Opioid analgesic combination